Peak6 Investments LLC Editas Medicine, Inc. Call Options Transaction History

Peak6 Investments LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$3.39 - $5.96 $210,519 - $370,116	-62,100 Reduced 38.26%	100,200 $341,000
Q2 2024 Aug 13, 2024	BUY	$4.67 - $7.28 $467,934 - $729,456	100,200 Added 161.35%	162,300 $757,000
Q1 2024 May 14, 2024	BUY	$7.03 - $11.07 $436,563 - $687,447	62,100 New	62,100 $460,000
Q3 2023 Nov 13, 2023	BUY	$6.92 - $9.31 $692 - $931	100 Added 0.53%	18,800 $146,000
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $118,932 - $214,489	18,700 New	18,700 $153,000
Q2 2022 Aug 12, 2022	SELL	$9.99 - $21.35 $253,746 - $542,290	-25,400 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$14.08 - $27.63 $66,176 - $129,861	-4,700 Reduced 15.61%	25,400 $483,000
Q2 2021 Aug 13, 2021	BUY	$31.29 - $56.64 $941,829 - $1.7 Million	30,100 New	30,100 $1.71 Million
Q1 2021 May 14, 2021	SELL	$39.71 - $90.58 $1.2 Million - $2.74 Million	-30,200 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$27.07 - $84.35 $817,514 - $2.55 Million	30,200 New	30,200 $2.12 Million

247

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $166M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Peak6 Investments LLC with notifications on news.